Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab for Prevention of Type 1 Diabetes in At-Risk Relatives
NCT01030861Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Aug 2010
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of teplizumab in type 1 diabetes mellitus (T1D), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Aug 2010; status: completed.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01030861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01030861.